Evaluation of Adjunctive Homoeopathy Treatment in COVID-19 Hospitalised Patients at the Gujarat State’s Dedicated COVID-19 Hospitals and Covid-Care Clinics During the First Wave of COVID-19 Pandemic: A Multicentric, Single-Arm Retrospective Data Analysis Study

Deepti Singh, A. Khurana, M. Trivedi, Pinaken Trivedi, Sarita Gola, Parul Singh
{"title":"Evaluation of Adjunctive Homoeopathy Treatment in COVID-19 Hospitalised Patients at the Gujarat State’s Dedicated COVID-19 Hospitals and Covid-Care Clinics During the First Wave of COVID-19 Pandemic: A Multicentric, Single-Arm Retrospective Data Analysis Study","authors":"Deepti Singh, A. Khurana, M. Trivedi, Pinaken Trivedi, Sarita Gola, Parul Singh","doi":"10.21926/obm.icm.2302025","DOIUrl":null,"url":null,"abstract":"This retrospective data analysis study aims to analyze the data collected during adjunctive homeopathy treatment of COVID-19 patients by the Homoeopathic medical officers (HMO) in Gujarat state-dedicated COVID-19 hospitals (DCH) during the first wave of the pandemic. The HMOs used the standard data collection forms/sheets to record each patient's demographic information, clinical symptoms, homoeopathic management, and outcome data. Data of all cases hospitalized with COVID-19 of any age, and both genders were included, and entries with missing values or incomplete/ incorrect information were excluded from the analysis. The outcome measure is the recovery duration, time to clinical improvement, worsening symptoms, and indicated homeopathic medicines. Data from 2581 cases analyzed showed clinical recovery time after adjunctive homeopathy as 05 days (IQR: 3-7); the Mean was 5.19 days (SD:4.62), with 80% of patients (2063 out of 2581) discharged between 0-7 days out of which more than 20.4% patients (419 out of 2063) having at least one of the comorbidities. Only 03 deaths of male patients above 50 years with comorbidities and 67 cases (2.6%) with worsening symptoms were reported. The homeopathic medicines used were Arsenic album in 73.0% and Bryonia alba in 17.6% of cases. Adjunctive Homoeopathy and standard care in COVID-19 patients had a promising role in the early relief of clinical symptoms and less progression into severity in the risk group of elderly patients with comorbidities. There were no reported adverse effects of taking the adjunctive Homoeopathy, making it a potential choice for integrated use in managing COVID-19 patients.","PeriodicalId":74333,"journal":{"name":"OBM integrative and complimentary medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OBM integrative and complimentary medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21926/obm.icm.2302025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This retrospective data analysis study aims to analyze the data collected during adjunctive homeopathy treatment of COVID-19 patients by the Homoeopathic medical officers (HMO) in Gujarat state-dedicated COVID-19 hospitals (DCH) during the first wave of the pandemic. The HMOs used the standard data collection forms/sheets to record each patient's demographic information, clinical symptoms, homoeopathic management, and outcome data. Data of all cases hospitalized with COVID-19 of any age, and both genders were included, and entries with missing values or incomplete/ incorrect information were excluded from the analysis. The outcome measure is the recovery duration, time to clinical improvement, worsening symptoms, and indicated homeopathic medicines. Data from 2581 cases analyzed showed clinical recovery time after adjunctive homeopathy as 05 days (IQR: 3-7); the Mean was 5.19 days (SD:4.62), with 80% of patients (2063 out of 2581) discharged between 0-7 days out of which more than 20.4% patients (419 out of 2063) having at least one of the comorbidities. Only 03 deaths of male patients above 50 years with comorbidities and 67 cases (2.6%) with worsening symptoms were reported. The homeopathic medicines used were Arsenic album in 73.0% and Bryonia alba in 17.6% of cases. Adjunctive Homoeopathy and standard care in COVID-19 patients had a promising role in the early relief of clinical symptoms and less progression into severity in the risk group of elderly patients with comorbidities. There were no reported adverse effects of taking the adjunctive Homoeopathy, making it a potential choice for integrated use in managing COVID-19 patients.
在第一波COVID-19大流行期间,古吉拉特邦专门的COVID-19医院和COVID-19护理诊所对COVID-19住院患者辅助顺势疗法治疗的评估:一项多中心、单臂回顾性数据分析研究
这项回顾性数据分析研究旨在分析第一波疫情期间古吉拉特邦新冠肺炎国家专门医院(DCH)的顺势疗法医生(HMO)在对新冠肺炎患者进行辅助顺势疗法治疗期间收集的数据。HMO使用标准数据收集表格/表格记录每位患者的人口统计信息、临床症状、顺势疗法管理和结果数据。纳入了所有因新冠肺炎住院的任何年龄和性别的病例的数据,分析中排除了缺失值或信息不完整/不正确的条目。结果指标是恢复持续时间、临床改善时间、症状恶化和适用的顺势疗法药物。来自2581例分析病例的数据显示,辅助顺势疗法后的临床恢复时间为05天(IQR:3-7);平均值为5.19天(SD:4.62),80%的患者(2581中的2063人)在0-7天之间出院,其中超过20.4%的患者(2063中的419人)至少有一种合并症。只有03例50岁以上合并症男性患者死亡,67例(2.6%)症状恶化。使用的顺势疗法药物是砷相册73.0%和白苔藓17.6%的病例。在患有合并症的老年患者风险组中,新冠肺炎患者的辅助性顺势疗法和标准护理在早期缓解临床症状和减少病情发展方面具有很好的作用。没有报告服用辅助顺势疗法的不良反应,这使其成为综合治疗新冠肺炎患者的潜在选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信